Global healthcare giants have committed roughly $500 billion to expand manufacturing and research across the United States, preparing for a shifting trade environment. Drugmakers are pouring capital into domestic infrastructure to mitigate supply-chain risks and secure tariff exemptions. The wave of investments follows federal administration pressure to onshore medical production and curb reliance on foreign facilities.

Drugmakers Scale Up Domestic Footprint